Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Budde

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 11, 2013
Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipientsH Tedesco-Silva, M M L Kho, A Hartmann, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 19, 2014
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS studyK Budde, F Lehner, C Sommerer, et al.
British Journal of Clinical Pharmacology|December 14, 1999
Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipientsH H Neumayer, K Paradis, A Korn, et al.
Lancet (London, England)|June 14, 2001
CC chemokine receptor 5 and renal-transplant survivalM Fischereder, B Luckow, B Hocher, et al.
Clinical Pharmacology and Therapeutics|June 5, 2009
UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patientsR H N van Schaik, M van Agteren, J W de Fijter, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 31, 2012
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS studyK Budde, F Lehner, C Sommerer, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 14, 2011
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipientsS Friman, W Arns, B Nashan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 12, 2012
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 yearF Vincenti, H Tedesco Silva, S Busque, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 16, 2007
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimusF Vincenti, S Friman, E Scheuermann, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2023
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 1506-1514, 2007F Vincenti, S Friman, E Scheuermann, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 11, 2013
Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipientsH Tedesco-Silva, M M L Kho, A Hartmann, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 19, 2014
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS studyK Budde, F Lehner, C Sommerer, et al.
British Journal of Clinical Pharmacology|December 14, 1999
Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipientsH H Neumayer, K Paradis, A Korn, et al.
Lancet (London, England)|June 14, 2001
CC chemokine receptor 5 and renal-transplant survivalM Fischereder, B Luckow, B Hocher, et al.
Clinical Pharmacology and Therapeutics|June 5, 2009
UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patientsR H N van Schaik, M van Agteren, J W de Fijter, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 31, 2012
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS studyK Budde, F Lehner, C Sommerer, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 14, 2011
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipientsS Friman, W Arns, B Nashan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 12, 2012
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 yearF Vincenti, H Tedesco Silva, S Busque, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 16, 2007
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimusF Vincenti, S Friman, E Scheuermann, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2023
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 1506-1514, 2007F Vincenti, S Friman, E Scheuermann, et al.
Pageof 16